189 related articles for article (PubMed ID: 23787099)
1. Identification of potent Yes1 kinase inhibitors using a library screening approach.
Patel PR; Sun H; Li SQ; Shen M; Khan J; Thomas CJ; Davis MI
Bioorg Med Chem Lett; 2013 Aug; 23(15):4398-403. PubMed ID: 23787099
[TBL] [Abstract][Full Text] [Related]
2. Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques.
Ramakrishnan C; Mary Thangakani A; Velmurugan D; Anantha Krishnan D; Sekijima M; Akiyama Y; Gromiha MM
J Biomol Struct Dyn; 2018 May; 36(6):1566-1576. PubMed ID: 28589758
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Yang X; Fan D; Troha AH; Ahn HM; Qian K; Liang B; Du Y; Fu H; Ivanov AA
Bioorg Med Chem; 2021 Sep; 45():116324. PubMed ID: 34333394
[TBL] [Abstract][Full Text] [Related]
4. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
5. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
[TBL] [Abstract][Full Text] [Related]
7. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
[TBL] [Abstract][Full Text] [Related]
8. Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors.
Kolb P; Kipouros CB; Huang D; Caflisch A
Proteins; 2008 Oct; 73(1):11-8. PubMed ID: 18384152
[TBL] [Abstract][Full Text] [Related]
9. Identification, structure modification, and characterization of potential small-molecule SGK3 inhibitors with novel scaffolds.
Gong GQ; Wang K; Dai XC; Zhou Y; Basnet R; Chen Y; Yang DH; Lee WJ; Buchanan CM; Flanagan JU; Shepherd PR; Chen Y; Wang MW
Acta Pharmacol Sin; 2018 Dec; 39(12):1902-1912. PubMed ID: 30038340
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
11. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
12. Identification of BRAF inhibitors through in silico screening.
Luo C; Xie P; Marmorstein R
J Med Chem; 2008 Oct; 51(19):6121-6127. PubMed ID: 18783202
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics.
Zhang W; Hu X; Chakravarty H; Yang Z; Tam KY
ACS Comb Sci; 2018 Nov; 20(11):660-671. PubMed ID: 30350563
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening.
Piala AT; Akella R; Potts MB; Dudics-Giagnocavo SA; He H; Wei S; White MA; Posner BA; Goldsmith EJ
Bioorg Med Chem Lett; 2016 Aug; 26(16):3923-7. PubMed ID: 27426302
[TBL] [Abstract][Full Text] [Related]
15. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
16. YES1 Is a Targetable Oncogene in Cancers Harboring
Hamanaka N; Nakanishi Y; Mizuno T; Horiguchi-Takei K; Akiyama N; Tanimura H; Hasegawa M; Satoh Y; Tachibana Y; Fujii T; Sakata K; Ogasawara K; Ebiike H; Koyano H; Sato H; Ishii N; Mio T
Cancer Res; 2019 Nov; 79(22):5734-5745. PubMed ID: 31391186
[TBL] [Abstract][Full Text] [Related]
17. Protocols for the Design of Kinase-focused Compound Libraries.
Jacoby E; Wroblowski B; Buyck C; Neefs JM; Meyer C; Cummings MD; van Vlijmen H
Mol Inform; 2018 May; 37(5):e1700119. PubMed ID: 29116686
[TBL] [Abstract][Full Text] [Related]
18. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.
Cui YH; Chen J; Xu T; Tian HL
Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417
[TBL] [Abstract][Full Text] [Related]
19. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.
Meyers MJ; Pelc M; Kamtekar S; Day J; Poda GI; Hall MK; Michener ML; Reitz BA; Mathis KJ; Pierce BS; Parikh MD; Mischke DA; Long SA; Parlow JJ; Anderson DR; Thorarensen A
Bioorg Med Chem Lett; 2010 Mar; 20(5):1543-7. PubMed ID: 20137931
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of 2-phenylisothiazolidin-3-one-1,1-dioxides as a new class of human protein kinase CK2 inhibitors.
Chekanov MO; Ostrynska OV; Synyugin AR; Bdzhola VG; Yarmoluk SM
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):338-43. PubMed ID: 23578312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]